AGGAME

Ê×Ò³ ÐÂÎÅ×ÊѶ ÆóÒµ¶¯Ì¬

AGGAMEÔÚÑÐÒÒ¸ÎÐÂÒ©GST-HG141ÄÎÈð¿ÉΤ ¢ñbÆÚÁÙ´²ÊÔÑéЧ¹ûÀֳɽÒÏþÓÚ¹ú¼ÊȨÍþ²¡¶¾Ñ§ÔÓÖ¾¡¶Virology Journal¡·

Ðû²¼£º2025-01-24¡¡|¡¡ÈªÔ´£º¡¡|¡¡ä¯ÀÀ£º1934

¿ËÈÕ £¬AGGAME£¨¼ò³Æ¡°AGGAMEÒ©Òµ¡±£©Á¢ÒìÒ©¿Ø¹É×Ó¹«Ë¾¸£½¨¹ãÉúÖÐÁØÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾µÄÒÒ¸ÎÖÎÁÆÁ¢ÒìÒ©GST-HG141£¨Ó¢ÎÄͨÓÃÃû ¡°Neracorvir¡± £¬ÖÐÎÄͨÓÃÃû ¡°ÄÎÈð¿ÉΤ¡±£©µÄ¢ñbÆÚÁÙ´²ÊÔÑéЧ¹ûÒѾ­ÀֳɽÒÏþ ¡£

GST-HG141ÄÎÈð¿ÉΤÊÇÐÂÐÍÒҸν¹µãÂѰ׻òºËÒ¿ǵ÷Àí¼Á £¬ÊôÓÚȫлúÖÆµÄÔÚÑп¹ÒҸβ¡¶¾Ò»ÀàÐÂÒ© ¡£Ëüͨ¹ýÆæÒìµÄ»úÖÆ £¬ÓÐÓõ÷ÀíÒҸβ¡¶¾½¹µãÂѰ׵Ĺ¹Ïó £¬½ø¶øÓ°Ï첡¶¾µÄ¸´ÖÆÀú³Ì £¬ÎªÒҸεÄÁÙ´²ÖÎÓúÌṩÁËеĽâ¾ö¼Æ»® ¡£2024Äê11Ô £¬GST-HG141ÄÎÈð¿ÉΤµÄÁÙ´²Ñо¿Ð§¹û±»¹ú¼ÊȨÍþרҵ»ú¹¹¡ªÃÀ¹ú¸Î²¡Ñо¿Ð­»á£¨AASLD£©×÷Ϊ×îÐÂÍ»ÆÆÕªÒª£¨Late-breaking Abstract£©ÐÎʽÔÚAASLDÄê»áÉϾÙÐÐչʾ£»2024Äê12Ô £¬GST-HG141ÄÎÈð¿ÉΤ±»¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄÄÉÈëÍ»ÆÆÐÔÖÎÁÆÆ·ÖÖÃûµ¥ £¬Î´À´ÓÐÍû³ÉΪȫÇòÒҸο¹²¡¶¾ÖÎÁÆÀï³Ì±®Ê½µÄÁ¢ÒìÒ© ¡£

¸ÃÒ©Îï¢ñÆÚÁÙ´²ÊÔÑéÔÚ¼ªÁÖ´óѧµÚÒ»Ò½Ôº£¨ÒÔϼò³Æ£º¼ª´óÒ»Ôº£©Ò»ÆÚÒ©ÎïÁÙ´²ÊÔÑ鲡·¿¿ªÕ¹ £¬ÓÉÅ£¿¡Ææ½ÌÊںͶ¡ÑÞ»ª½ÌÊÚÖ÷³ÖÍê³É²¢×÷ΪÅäºÏͨѶ×÷Õß½«Ñо¿Ð§¹û½ÒÏþÔÚ¡¶Virology Journal¡·ÔÓÖ¾ £¬2024Äê12ÔÂ20ÈÕÕýʽÏßÉϹûÕæ £¬ÎÄÕ±íÌâΪ¡¶Safety, pharmacokinetics, and antiviral effficacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized,placebo-controlled design¡· ¡£

¸ÃÑо¿Îª¶àÖÐÐÄ¡¢Ëæ»ú¡¢Ë«Ã¤¡¢Î¿½å¼Á±ÈÕյĶà¼ÁÁ¿¡¢¶à´Î¸øÒ©µÄÄÍÊÜÐÔ¡¢Ò©´ú¶¯Á¦Ñ§ºÍҩЧѧµÄ¢ñbÆÚÁÙ´²ÊÔÑéÑо¿ £¬Ö¼ÔÚÆÀ¼ÛGST-HG141ƬÔÚÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÖжà´Î¸øÒ©µÄÄÍÊÜÐÔ¡¢ÆðԴҩЧѧºÍÒ©´ú¶¯Á¦Ñ§ÌØÕ÷ ¡£

Ñо¿¹²ÄÉÈë30ÀýÂýÐÔÒÒÐ͸ÎÑ×(CHB£©³õÖλ¼Õß×÷ΪÊÜÊÔÕß £¬¹²ÉèÖÃ3¸öGST-HG141¼ÁÁ¿×é £¬»®·ÖΪ25 mg BID£¨µÚÒ»×飩¡¢50 mg BID£¨µÚ¶þ×飩¡¢100 mg BID£¨µÚÈý×飩¼ÁÁ¿×é £¬Ã¿×é¸÷ÄÉÈë10ÀýÊÜÊÔÕߣº8Àý½ÓÊÜÊÔÑéÒ©Îï £¬2Àý½ÓÊÜο½å¼Á ¡£¸÷¼ÁÁ¿×éÒ»Á¬¸øÒ©28Ìì £¬µÚ1Ìì-µÚ27ÌìÌìÌì¸øÒ©2´Î £¬¸øÒ©¾àÀë12Сʱ £¬µÚ28ÌìÔçÉϸøÒ©Ò»´Î £¬²Íºó¸øÒ© ¡£


Ñо¿Ð§¹ûÏÔʾGST-HG141 ÔÚËùÓмÁÁ¿Ï¾ùÌåÏÖ³öÓÅÒìµÄÇå¾²ÐÔºÍÄÍÊÜÐÔ


ÔÚ28ÌìÓÃҩʱ´úûÓÐÊÜÊÔÕß·ºÒòÓÉÒ©Îï²»Á¼·´Ó¦ (ADR) µ¼ÖµÄéæÃü¡¢ÑÏÖØ²»Á¼ÊÂÎñ»òÍ£Ò©µÄÇéÐÎ £¬Î´±¬·¢¼¡ËáÁ×ËἤøÔö¸ßµÄ²»Á¼·´Ó¦ ¡£¸÷¼ÁÁ¿×é²»Á¼·´Ó¦±¬·¢ÂÊÎÞÏÔ×Ųî±ð £¬ÇÒÓëο½å¼Á×éÎÞͳ¼ÆÑ§²î±ð ¡£Î´¼ûÓë¼ÁÁ¿Ïà¹ØÐÔ²»Á¼·´Ó¦ £¬ËùÓв»Á¼ÊÂÎñ¾ùΪÇá¶È £¬±¬·¢ÂʺÍÑÏÖØË®Æ½²¢Î´Ëæ¼ÁÁ¿ÔöÌí¶øÉý¸ß¡¢¼ÓÖØ ¡£³£¼û²»Á¼ÊÂÎñ°üÀ¨ÖÐÐÔÁ£Ï¸°û¼ÆÊýïÔÌ­£¨12.5%£©¡¢°×ϸ°û¼ÆÊýïÔÌ­£¨8.3%£©¡¢µÍÁ×Ѫ֢£¨8.3%£©¡¢±û°±Ëá°±»ù×ªÒÆÃ¸Ë®Æ½Éý¸ß£¨8.3%£©ºÍÌìÃŶ¬°±Ëá°±»ù×ªÒÆÃ¸Ë®Æ½Éý¸ß£¨8.3%£© ¡£

AGGAME¡¤(ÖйúÇø)¼¯ÍŹٷ½ÍøÕ¾

Ñо¿ÒÔΪ £¬ÔÚÂýÐÔÒÒÐ͸ÎÑ×»¼ÕßÖÐ £¬ GST-HG141µÄ¼ÁÁ¿×ÝÈ»¸ß´ï100mg £¬ ÆäÇå¾²ÐÔÈÔ¿É¿¿ £¬ÎÞÏÔ×ŵÄÑÏÖØÇå¾²ÐÔÎÊÌâ ¡£´ó´ó¶¼²»Á¼ÊÂÎñΪÇá¶ÈÖÁÖжȣ¨1 ¼¶»ò 2 ¼¶£© £¬ÇÒ±¬·¢ÆµÂÊ»òÑÏÖØË®Æ½¶¼Ã»ÓÐÏÔ×ŵļÁÁ¿Ïà¹ØÇ÷ÊÆ ¡£Î´·¢Ã÷ת°±Ã¸Ë®Æ½Éý¸ßÓйصÄÑÏÖØ²»Á¼·´Ó¦ ¡£


GST-HG141¾ßÓкÜÇ¿µÄ¿¹²¡¶¾»îÐÔ £¬CHB»¼ÕßÖÎÁÆ28Ìì¿É´ó·ù½µµÍHBV DNA ºÍ HBV pgRNA µÄˮƽ


ÔÚÖÎÁÆÊ±´ú £¬25mg BID×é¡¢50mg BID×é¡¢100mg BID 3¸ö¼ÁÁ¿×éÊÜÊÔÕßµÄHBV DNA ˮƽ¾ùÒ»Á¬½µµÍ £¬ÔÚµÚ 29 ÌìµÖ´ï×îµÍˮƽ £¬Óë»ùÏßÏà±ÈµÄ½µµÍ·ù¶È»®·ÖΪ -3.01 (0.47) log10 IU/mL¡¢-2.92 (1.26) log10 IU/mL¡¢-3.43 (0.55)log10 IU/mL £¬25mg BID×é¡¢50mg BID×éHBV DNAϽµË®Æ½ÎÞÏÔ×Ųî±ð £¬100mg BID×éHBV DNAϽµË®Æ½ÂÔÓÅÓÚǰ2¸ö¼ÁÁ¿×é ¡£Í£Ò©ºó5Ìì·ºÆð²î±ðˮƽµÄ·´µ¯ £¬µ«Ëæ×ÅÖÎÁƼÁÁ¿Éý¸ß £¬·´µ¯ËÙÂʽµµÍ ¡£

3¸ö¼ÁÁ¿×éÊÜÊÔÕßµÄHBV pgRNA¾ù½Ï»ùÏß½µµÍ £¬½µµÍ·ù¶ÈÏÔ×ÅÓÅÓÚο½å¼Á×é £¬ÔÚµÚ29Ììʱ £¬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éÓë»ùÏßÏà±ÈHBV pgRNAµÄ½µµÍ·ù¶È»®·ÖΪ-1.71 (1.003) log10 IU/mL¡¢-1.93 (0.899) log10 IU/mL¡¢-2.37 (0.784) log10 IU/mL £¬½µµÍ·ù¶È¾ßÓÐÒ»¶¨¼ÁÁ¿Ïà¹ØÐÔ ¡£

¸÷¼ÁÁ¿×éHBeAg¾ù½Ï»ùÏßϽµ £¬Ï½µË®Æ½ÏÔ×ÅÓÅÓÚο½å¼Á×é £¬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éÓë»ùÏßÏà±ÈHBeAgµÄ½µµÍ·ù¶È»®·ÖΪ-0.08 (0.119) log10 U/mL¡¢-0.05 (0.063) log10 U/mL¡¢-0.09 (0.099) log10 U/mL £¬¸÷¼ÁÁ¿×éϽµË®Æ½ÎÞÏÔ×Ųî±ð ¡£¸÷¼ÁÁ¿×éHBcrAg½Ï»ùÏß¾ùϽµ £¬Ï½µË®Æ½ÏÔ×ÅÓÅÓÚο½å¼Á×é £¬ÔÚµÚ29Ììʱ £¬25mg BID×é¡¢50mg BID×é¡¢100mg BID×éHBcrAg½Ï»ùÏ߯½¾ùÖµ£¨±ê×¼²î£©½µ·ù»®·ÖΪ-0.25  log10 IU/mL¡¢-0.30log10 IU/mL¡¢-0.25 log10 IU/mL £¬¸÷¼ÁÁ¿×éϽµË®Æ½ÎÞÏÔ×Ųî±ð ¡£

AGGAME¡¤(ÖйúÇø)¼¯ÍŹٷ½ÍøÕ¾


Ò©´ú¶¯Á¦Ñ§ÆÊÎöÅú×¢ £¬GST-HG141ѪҩŨ¶ÈÔÚ25~50mg BID¹æÄ£ÄÚ³ÊÏßÐÔ¹ØÏµÇ÷ÊÆ £¬ÇҸùæÄ£Ä򵀮½¾ù¹ÈŨ¶È×ãÒÔÁýÕÖÂѰ×ÍŽáµ÷½âºóµÄEC50


25mg BID¡¢50mg BIDºÍ100mg BIDÒ»Á¬¸øÒ©28Ìì £¬Ñª½¬ÖÐGST-HG141ÖÐλ´ï·åʱ¼äΪ3.0 ~ 3.5Сʱ£¨µÚ1Ì죩ºÍ2.0~ 3.5Сʱ£¨µÚ28Ì죩 £¬µÚ 8 Ìì µÖ´ïÎÈ̬ £¬GST-HG141ÔÚÌåÄÚÓÐÉÔ΢µÄÐî»ý ¡£µÚ 28 Ìì £¬25mg BID¡¢50mg BIDºÍ100mg BID ×éÊÜÊÔÕßµÄGST-HG141ƽ¾ù¹ÈŨ¶È»®·Ö±ÈÆäÂѰ×ÍŽáµ÷½âºóµÄ HBV DNA EC50£¨17ng/ mL£©¸ß 4.4¡¢11.1 ºÍ 14.6 ±¶ ¡£

AGGAMEÒ©Òµ¸ß¶ÈÖØÊÓGST-HG141ÄÎÈð¿ÉΤµÄÑз¢ÊÂÇé £¬×èÖ¹±¾¸åÐû²¼ÈÕ £¬AGGAMEÒѾ­Íê³ÉÁË´ÓÁÙ´²Ç°Ñо¿µ½IIÆÚÁÙ´²ÊÔÑéµÄËùÓÐÊÂÇé £¬ÇÒIIÆÚÁÙ´²ÊÔÑéµÄÑо¿×ܽᱨ¸æÏÔʾGST-HG141ÄÎÈð¿ÉΤ¹ØÓÚÂýÐÔÒÒÐ͸ÎÑ׵Ͳ¡¶¾ÑªÖ¢»¼Õß¾ßÓÐÓÅÒìµÄÇå¾²ÐÔºÍÏÔÖøÒ©Ð§ £¬¶ÔHBV DNAµÄÒÖÖÆÐ§¹ûÏÔÖøÓÅÓÚÏÖÔÚÁÙ´²ÖÎÁÆÍƼöºËÜÕ£¨ËᣩÀàËÆÎïµ¥Ò©ÖÎÁƱÈÕÕ×é £¬ÔÚÒҸλ¼ÕßÉÏÈ·Ö¤ÁËÆäÔÚºËÜÕ£¨ËᣩÀàÒ©ÎïÖÎÁÆ»ù´¡ÉϽøÒ»²½ÒÖÖÆHBV DNA¸´ÖƺÍDZÔںĽßcccDNAµÄ×÷Óà £¬ÁÙ´²Ñо¿µÖ´ïÔ¤ÆÚÄ¿µÄ £¬Êý¾ÝÓÅÒì ¡£¹«Ë¾½«¼ÌÐø±ü³Ö¿ÆÑ§¡¢ÑϽ÷µÄÑз¢Ì¬¶È £¬¼ÓËÙÐÂÒ©Ñз¢Àú³Ì £¬ÎªÈ«ÇòÒҸλ¼ÕßÌṩ¸ü¶à¡¢¸üºÃµÄÖÎÁÆÑ¡Ôñ ¡£ 



²Î¿¼ÎÄÏ×

Wu et al. Safety, pharmacokinetics, and antiviral efffcacy of the novel capsid assembly modulator GST-HG141 in patients with chronic hepatitis B: a phase 1 trial with a randomized,placebo-controlled design.Virology Journal (2024) 21:328 https://doi.org/10.1186/s12985-024-02584-8

Ïà¹ØÐÂÎÅ

ÁªÏµ·½·¨
µç»°£º0591-38265199
´«Õ棺0591-83228265
ҽѧ×ÉѯÈÈÏߣº400-8875-001
²»Á¼·´Ó¦±¨¸æ£ºÓÊÏ䣺pvd@cosunter.com£»pv@akeylink.cn ÔÚÏßÌ£ºÁ´½Ó
Ò½Ò©´ú±í±¸°¸£ºÁ´½Ó
¹«Ë¾µØµã£º¸£½¨Ê¡¸£ÖݸßÐÂÇøÎÚÁú½­ÖдóµÀ7ºÅÁ¢ÒìÔ°¶þÆÚ16ºÅÂ¥
Éú²ú»ùµØ£º¸£½¨Ê¡èÏÈÙÏØ¶«Ô´Ï縻Դ¹¤ÒµÇø
ɨÂë¹Ø×¢

AGGAME΢ÐŹ«ÖÚºÅ

AGGAME¸ÊÓÑÖ®¼Ò΢ÐŹ«ÖÚºÅ
×ʸñÖ¤Êé±àºÅ£º(Ãö)-·Çı»®ÐÔ-2014-0006 2015 AGGAME ÃöICP±¸11026770ºÅ

Ãö¹«Íø°²±¸ 35092602000113ºÅ

ÍøÕ¾µØÍ¼